What is aggressive NK-cell leukaemia?
Aggressive NK-cell leukaemia (ANKL) is a very rare and fast-growing blood cancer of natural killer (NK) cells. NK cells are white blood cells that normally help the body fight viruses and destroy abnormal cells. In ANKL, cancerous NK cells multiply rapidly and spread through the blood, bone marrow, liver and spleen.
ANKL is closely linked with the Epstein-Barr virus (EBV), the virus that causes glandular fever, and the virus is found inside the cancer cells in most cases. The disease is more common in East Asia than in Europe or North America, and it often affects younger and middle-aged adults (Ishida, 2018).
People usually become very unwell within days or weeks, with high fever, liver problems and low blood counts. For many years, the median survival was less than three months. Today, chemotherapy containing L-asparaginase followed by an allogeneic stem cell transplant offers some patients the chance of remission and possible cure.
ANKL is classified with the mature T-cell and NK-cell neoplasms. Because it is so rare, care should be given in a specialist haematology centre.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Leukaemia of mature natural killer cells |
| How common | Very rare; more frequent in East Asia |
| Typical age | Young and middle-aged adults; median around 40 in Asian series |
| Sex | Affects men and women |
| Linked virus | Epstein-Barr virus in most cases |
| Main sites | Blood, bone marrow, liver, spleen |
| Typical presentation | High fever, enlarged liver and spleen, jaundice, low blood counts |
| Main treatment | L-asparaginase-based chemotherapy and allogeneic stem cell transplant |
| Outlook | Poor; survival is often measured in months without transplant |
2. NK-cell cancers compared
| Condition | Main sites | Course | Outlook |
|---|---|---|---|
| Aggressive NK-cell leukaemia | Blood, marrow, liver, spleen | Very rapid | Poor |
| Extranodal NK/T-cell lymphoma | Nose, throat, skin, gut | Rapid, but often localised at first | Better if localised |
| Chronic lymphoproliferative disorder of NK cells | Blood | Slow, often without symptoms | Good |
3. Causes and risk factors
The exact cause of ANKL is not fully understood. Several factors are thought to play a part.
| Factor | Notes |
|---|---|
| Epstein-Barr virus | Infects the NK cells and helps drive their growth |
| Geography and ancestry | More common in people from East Asia and parts of Central and South America |
| Chronic active EBV infection | A rare long-lasting EBV illness that can progress to ANKL |
| Gene changes in the cancer cells | Changes in the JAK-STAT pathway and other signalling routes |
ANKL is not inherited and not contagious. EBV infects most adults worldwide, and almost everyone with EBV never develops ANKL.
4. How does it look
In the body
| Feature | Description |
|---|---|
| Enlarged liver and spleen | Very common; the spleen may be felt under the left ribs |
| Jaundice | Yellowing of the skin and eyes from liver involvement |
| Lymph nodes | Sometimes enlarged |
| Skin | Rash or nodules are uncommon |
| Fluid build-up | Swelling of the abdomen or around the lungs in some patients |
Under the microscope
| Feature | Description |
|---|---|
| Blood film | Abnormal large granular lymphocytes, sometimes with very atypical features |
| Bone marrow | Infiltration by NK cells, which may be patchy |
| Haemophagocytosis | Immune cells engulfing blood cells, a sign of an overactive immune response |
| Liver biopsy | NK cells in the liver sinusoids |
Laboratory markers
| Marker | Typical result |
|---|---|
| CD56 | Positive |
| Surface CD3 | Negative (distinguishes NK cells from T cells) |
| Cytoplasmic CD3 epsilon | Positive |
| Cytotoxic granule proteins | Positive (granzyme B, perforin, TIA-1) |
| EBER in situ hybridisation | Positive in most cases |
| T-cell receptor gene studies | No clonal rearrangement |
The proportion of leukaemic cells in the blood and marrow can be low. In one Japanese and Korean study, 11 of 34 patients had fewer than 20% abnormal cells in both blood and marrow, yet their outcomes were similar to the others (Ishida et al., 2012).
5. Symptoms
Symptoms usually appear suddenly and get worse quickly.
Common symptoms
- High fever that does not settle with antibiotics
- Night sweats and weight loss
- Tiredness and weakness
- Pain or fullness under the ribs from an enlarged liver or spleen
- Yellow skin and eyes
- Easy bruising or bleeding
- Frequent infections
Serious complications
| Complication | What happens |
|---|---|
| Haemophagocytic lymphohistiocytosis (HLH) | An overactive immune reaction causing fever, low blood counts and organ damage |
| Disseminated intravascular coagulation (DIC) | Abnormal blood clotting and bleeding |
| Liver failure | Jaundice, confusion, fluid build-up |
| Multi-organ failure | Kidneys, lungs and other organs may stop working properly |
These complications explain why many patients are critically ill at diagnosis.
Understanding HLH
Haemophagocytic lymphohistiocytosis (HLH) happens when the immune system becomes dangerously overactive. Immune cells release large amounts of inflammatory chemicals and start destroying the body’s own blood cells. This causes persistent fever, an enlarged spleen, low blood counts, very high ferritin and liver damage.
In ANKL, HLH is triggered by the cancer cells and EBV. Treating HLH quickly can stabilise patients so they are well enough for chemotherapy.
When to seek medical advice
Seek urgent medical care for a high fever lasting several days, especially with yellow skin, bleeding, severe tiredness or pain under the ribs. Most fevers have simple causes, but these combinations need prompt investigation.
6. Diagnosis
| Test | Purpose |
|---|---|
| Full blood count and blood film | Shows low counts and abnormal lymphocytes |
| Flow cytometry | Identifies NK cells by their surface markers |
| Bone marrow biopsy | Confirms infiltration and checks for haemophagocytosis |
| Liver tests and clotting tests | Assess liver damage and DIC |
| Ferritin, triglycerides, fibrinogen | Help detect HLH |
| Plasma EBV DNA | Measures virus levels, which reflect disease burden |
| PET-CT | Shows involved organs |
| Liver or spleen biopsy | When marrow findings are unclear |
The two main conditions to tell apart are extranodal NK/T-cell lymphoma with spread and chronic active EBV infection. Because the disease moves fast, specialists aim to make the diagnosis within days.
The role of EBV testing
Measuring EBV DNA in the blood is one of the most useful tests in ANKL. High levels at diagnosis reflect a large amount of cancer. During treatment, a falling level suggests the treatment is working, while a rising level can be an early sign of relapse. The aim of treatment is to make the virus undetectable in the blood, alongside a clear PET-CT scan (Tse et al., 2022).
7. Treatment
Treatment must begin as soon as possible and is given in a specialist haematology unit, often with intensive care support.
Supportive care
| Problem | Management |
|---|---|
| HLH | Steroids, sometimes etoposide, and other immune-calming drugs |
| Bleeding and DIC | Platelet and plasma transfusions |
| Infections | Antibiotics, antifungals and antivirals |
| Organ failure | Intensive care support |
Chemotherapy
| Approach | Notes |
|---|---|
| L-asparaginase-based regimens | The backbone of treatment, for example SMILE, DDGP or similar combinations |
| Avoiding anthracycline-based regimens alone | NK-cell cancers resist many standard drugs, so CHOP-like regimens work poorly |
| Dose adjustment | Often needed because of liver problems and frailty |
NK-cell cancers often carry a multidrug resistance pattern, which is why anthracycline-based treatment is ineffective and asparaginase-containing regimens are preferred (Tse et al., 2022).
In a Korean study of 51 patients, L-asparaginase regimens produced responses in about 47%, compared with about 21% for other regimens. Seven patients died before chemotherapy could begin (Yoon et al., 2025).
Allogeneic stem cell transplant
An allogeneic stem cell transplant uses healthy blood stem cells from a donor. It is currently the best chance of long-term remission.
| Study | Finding |
|---|---|
| Japan-Korea study, 34 patients | Median survival was 266 days with transplant and 36 days without (Ishida et al., 2012) |
| Korean study, 51 patients | Responders who went on to transplant lived longer than those who did not (Yoon et al., 2025) |
What happens during a stem cell transplant
| Stage | What happens |
|---|---|
| Finding a donor | Tissue typing of siblings and searches of donor registries |
| Conditioning | High-dose chemotherapy, sometimes with radiotherapy, to clear the marrow |
| Transplant day | Donor stem cells are given through a drip, like a blood transfusion |
| Engraftment | Over 2-4 weeks, the new cells start making blood |
| Early recovery | Several weeks in hospital with protection from infection |
| Longer recovery | Months of close follow-up as the new immune system matures |
The donor’s immune cells can also attack remaining cancer cells. This graft-versus-leukaemia effect is one reason why transplant can work when chemotherapy alone does not.
Relapsed or resistant disease
| Option | Notes |
|---|---|
| PD-1 inhibitors | Such as pembrolizumab; under study in NK-cell cancers |
| EBV-specific T-cell therapy | Experimental |
| JAK inhibitors and other targeted drugs | Experimental, based on gene changes |
| Clinical trials | Strongly encouraged |
Side effects
| Treatment | Possible side effects |
|---|---|
| L-asparaginase | Allergic reactions, clotting problems, pancreatitis, liver strain, high blood sugar |
| Other chemotherapy | Infections, bleeding, sickness, hair loss |
| Stem cell transplant | Graft-versus-host disease, infections, organ damage |
8. Outlook (prognosis)
| Measure | Finding |
|---|---|
| Historical median survival | Less than 3 months (Ishida, 2018) |
| Median survival, Japan-Korea series | 51 days for all 34 patients (Ishida et al., 2012) |
| Median overall survival, Korean series | 1.6 months for 51 patients (Yoon et al., 2025) |
| Best outcomes | Patients who respond to asparaginase chemotherapy and then have a transplant |
ANKL remains one of the most serious blood cancers. Poor general health at diagnosis is common; in the Korean series, over a third of patients were too unwell to carry out most daily activities when first seen (Yoon et al., 2025). Early diagnosis and fast referral are therefore important.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Plasma EBV DNA | Undetectable levels suggest good control |
| PET-CT | Checks response to treatment |
| Bone marrow tests | Confirms remission |
| Transplant follow-up | Monitors graft-versus-host disease, infections and organ function |
10. Living with aggressive NK-cell leukaemia
- Stay close to your treatment centre during intensive treatment
- Report fever immediately, as infections can become serious quickly
- Follow infection precautions: hand washing, food safety and avoiding sick contacts
- Take preventive medicines such as antivirals and antifungals as prescribed
- Ask about palliative care early; it helps with symptoms and support alongside active treatment
- Eat well and keep moving as much as you can; a dietitian and physiotherapist can help you stay strong
- Keep a thermometer at home and know the temperature at which to call the hospital
- Seek emotional support for yourself and your family from psychologists, social workers and blood cancer charities
After a transplant
| Topic | Advice |
|---|---|
| Medicines | Take immune-suppressing drugs exactly as prescribed |
| Vaccinations | Re-vaccination usually begins months after transplant |
| Sun protection | Important, as skin graft-versus-host disease can be triggered by sunlight |
| Returning to work | Often takes many months |
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is ANKL contagious? | No. EBV is common, but the cancer itself cannot spread to others |
| Did glandular fever cause it? | EBV is involved, but almost everyone with EBV never develops ANKL |
| Is it inherited? | No; the changes that cause it develop during life and are not passed on |
| Why is a transplant needed? | Chemotherapy alone rarely keeps ANKL away |
| Can I find a donor? | Siblings, unrelated donors, half-matched family members or cord blood may be options |
| Can children get ANKL? | It is very rare in children; teenagers are occasionally affected |
| How long is treatment? | Usually a few cycles of chemotherapy, then a transplant if possible, followed by a long recovery |
| Are there new treatments? | Immunotherapy and targeted drugs are being studied |
12. Questions to ask your care team
- How certain is the diagnosis?
- Which chemotherapy do you recommend, and why?
- Am I suitable for a stem cell transplant?
- Has a donor search started?
- Is there a clinical trial I could join?
- How will we know whether the treatment is working?
- What are the signs of infection or bleeding I should report straight away?
- What support is available for my family?
Resources
- Ishida, F. (2018) ‘Aggressive NK-cell leukemia’, Frontiers in Pediatrics, 6, 292.
- Ishida, F. et al. (2012) ‘Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation’, Cancer Science, 103(6), pp. 1079-1083.
- Tse, E. et al. (2022) ‘How we treat NK/T-cell lymphomas’, Journal of Hematology & Oncology, 15(1), 74.
- Yoon, S.E. et al. (2025) ‘Aggressive natural killer cell leukemia therapy in the L-asparaginase era: why are we failing?’, Blood Research, 60(1), 55.
- National Cancer Institute (2026) Peripheral T-Cell Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/peripheral-t-cell-lymphoma-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.